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ABSTRACT 
Background: Cystoid macular edema (CME), a common complication of branch retinal vein occlusion (BRVO), is associated 
with a significant vision loss. Anti-vascular endothelial growth factor (anti-VEGF) therapy is the gold standard of treatment, 
while grid macular photocoagulation has also been used as an adjuvant in patients with CME secondary to BRVO. More 
recent efforts were successful by the use of intravitreal triamcinolone acetonide. We proposed a concurrent use of 
intravitreal triamcinolone acetonide and intravitreal bevacizumab in the treatment of CME secondary to BRVO.  
Case presentation: We described an 82-year-old female with a BRVO in the right eye who developed associated CME. 
Repeated injections of intravitreal bevacizumab and modified grid macular laser treatment were ineffective. A concurrent 
treatment with intravitreal bevacizumab and triamcinolone acetonide resulted in complete and dramatic resolution of 
CME with a favorable visual outcome. Optical Coherence Tomography (OCT) demonstrated a significant decrease in central 
subfield thickness (CST) from 764μm to 253μm, without any post-procedure complications or recurrence of macular 
edema with complete recovery of visual acuity at 6-month follow-up. 
Conclusion: Early concurrent treatment with intravitreal anti-VEGF therapy (e.g. intravitreal bevacizumab) and intravitreal 
triamcinolone acetonide is likely to be more effective than intravitreal anti-VEGF agents alone or grid macular 
photocoagulation in the management of CME associated with BRVO. 
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INTRODUCTION
Branch retinal vein occlusion (BRVO), the second most 
common cause of retinal vascular disease, is a frequent cause 
of vision loss, which could impact quality of life to a great 
extent [1]. Classic clinical features include sectoral retinal 
hemorrhages and dilated, tortuous retinal veins along with 
cotton-wool spots in the distribution of the occluded vessel [2]. 
BRVO causes both retinal ischemia and inflammation [3]. 
Release of inflammatory mediators such as interleukin-1 (IL-1), 
interleukin-6 (IL-6), monocyte chemoattractant protein-1 
(MCP-1), intracellular adhesion molecule-1 (ICAM-1), and 
vascular endothelial growth factor (VEGF) result in an increase 
in vascular permeability and disruption of the blood-retinal 
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barrier with subsequent retinal edema, as well as endothelial 
damage with aggravation of ischemia and non-perfusion [3, 4]. 
Since macular edema is a leading cause of visual impairment in 
patients with BRVO, various management strategies targeted 
towards its underlying inflammatory mediators. Grid macular 
laser has been commonly used for the treatment of BRVO-
associated CME with mixed visual outcomes [5]. More 
recently, intravitreal triamcinolone acetonide or intravitreal 
injections of antibodies targeting VEGF are used in the 
management of BRVO-associated CME in an effort to improve 
visual outcomes [2]. However, macular edema sometimes 
recurs despite treatment with anti-VEGF therapy. 
We reported a patient with a dramatic and rapid resolution of 
CME after a single injection of concurrent intravitreal Avastin 
(Genentech, bevacizumab 1.25 mg) and Triesence (Alcon, 
triamcinolone acetonide 2 mg), which was resistant to grid 
photocoagulation and anti-VEGF therapy. 
 
CASE PRESENTATION 
An 82-year-old female with a history of bilateral pseudophakia, 
gout, and hyperlipidemia using simvastatin, presented to the 
Loma Linda University Eye Institute due to a 4-day history of 
poor vision in the right eye associated with distortion in the 
inferior visual field. Best-corrected visual acuity (BCVA) were 
20/40+2 and 20/25-2 in the right (OD) and left (OS) eyes, 
respectively. Examination of pupils, confrontational visual 
fields (CVF), and extraocular motility (EOM) was 
unremarkable. Slit lamp examination (SLE) showed anterior 
capsular phimosis in the right eye. Fundoscopy revealed a 
BRVO associated with macular edema and intraretinal 
hemorrhages along the superior arcade in the right eye 
(Figure1). Ocular Coherence Tomography (OCT; Heidelberg 
Engineering Inc., Heidelberg, Germany) of the macula revealed 
CME with intraretinal cysts involving the superior aspect of the 
fovea with Central Foveal Thickness (CFT) of 368 μm. One week 
later, BCVA in the right eye declined to 20/70+1 and OCT 
demonstrated worsening of CME. Fluorescein angiography 
(FA) revealed delayed venous filling of the superior venous 
arcade with overlying leakage, capillary non-perfusion, and 
cystoid macular edema (Figure 2B). The patient was treated 
with monthly intravitreal Avastin (1.25mg/0.05 mL) for three 
months. In addition, grid focal macular laser was applied; laser 
power was titrated to produce light white-gray burns (the 
maximum power of 180 miliwatts with a spot size of 50 
microns and duration of 100 miliseconds) in areas of non-
perfusion to improve the macular edema.  
However, BCVA in the right eye continued to decline and was 
20/100 at the 12-week follow-up. OCT revealed continued 
worsening of cystoid macular edema in the right eye with CFT 
of 764μm (Figure 2A). After obtaining an ethical approval, 
concurrent intravitreal bevacizumab and intravitreal 
triamcinolone acetonide, was administered in the right eye. 
Five weeks after therapy, complete resolution of cystoid 
macular edema was noted; OCT demonstrated CFT 
improvement from 764μm to 253μm (Figure 3). BCVA in the 
right eye improved to 20/20-1 at 6-month follow-up. 
 
DISCUSSION 
Cystoid macular edema is a major cause of poor vision in 
patients with a BRVO. Laser photocoagulation remains a safe 
therapy, but visual outcomes have been delayed compared to 
anti-VEGF therapy or results might be unsatisfactory [2, 4]. 
However, there is insufficient evidence illustrating the benefit 
of intravitreal anti-VEGF agents over grid laser 
photocoagulation in macular edema associated with BRVO [6]. 
In our case, we modified previously reported approaches in 
the treatment of BRVO-associated CME due to inadequate 
response to conventional treatment with anti-VEGF therapy 
coupled with macular grid photocoagulation. We concurrently 
administered intravitreal bevacizumab and triamcinolone 
acetonide, in an effort to successfully resolve the macular 
edema. Complete resolution of the CME and significant 
improvement of the vision was accomplished without any 
associated post-procedure complications or recurrence. These 
results indicate that this method is an encouraging approach 
to the treatment of recalcitrant CME secondary to BRVO. 
 
 
Figure 1: Fundus photograph of the right eye of 82-year-old female 
showing superior temporal branch vein occlusion with macular 
edema and multiple intraretinal hemorrhages. Tortuous retinal 
veins has been noted. 
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Figure 2: Before concurrent treatment with intravitreal bevacizumab and triamcinolone acetonide. A) 3-D ocular coherence tomography (OCT) of macula 
showing severe, recalcitrant cystoid macular edema. B) Late-phase fluorescein angiography (FA) showing capillary dropout and leakage along the superior 
venous arcade with superior cystoid macular edema. 
 
 
Retinal vascular occlusion results in an acute release of 
inflammatory mediators such as IL-1, IL-6, MCP-1, ICAM-1, 
and VEGF [7]. These cytokines alter vascular permeability 
with resultant intraretinal edema, leukocyte infiltration and 
tissue remodeling. The foveal avascular zone is vulnerable 
and often results in clinically significant macular edema 
(CSME) with reduction in vision. Goals of management 
include alleviation of hypoxia, neutralization of VEGF and 
inhibition of production of inflammatory cytokines [2]. 
Grid macular photocoagulation is one of the preferred 
treatments of BRVO-associated macular edema. 
Photocoagulation of photoreceptors decreases the oxygen 
demand of the outer retina and increases diffusion of oxygen 
from the choroid to the inner retina [8, 9]. Increased 
oxygenation results in autoregulatory constriction of 
arterioles, increased intravascular resistance, and reduced 
hydrostatic pressure [7]. Additionally, decrease in 
intravascular hydrostatic pressure (Starling’s hypothesis) 
across the capillary wall reduces the intraretinal edema. 
However, treatment of BRVO-associated macular edema 
with grid macular photocoagulation can be ineffective due to 
continued production of vasopermeability factors from the 
hypoxic retina with resultant macular edema in the setting of 
BRVO [7].  
 
 
 
Figure 3: Five weeks after concurrent treatment with intravitreal 
bevacizumab and triamcinolone acetonide. 3-D ocular coherence 
tomography (OCT) of macula showing complete resolution of severe, 
recalcitrant cystoid macular edema. 
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VEGF released by retinal glial and Müller cells in a hypoxic 
state results in alteration of tight junctions between 
retinal vascular endothelial cells and a consequential 
increase in endothelial permeability [7]. Anti-VEGF 
therapy is very effective in neutralizing VEGF, a common 
cytokine produced after an ischemic insult such as BRVO. 
However, it has no effect on other inflammatory cytokines 
such as IL-6 and ICAM-1 [4]. Aqueous levels of IL-6 are 
significantly elevated in BRVO compared to controls and 
its expression results in alteration of gap junctions and an 
increase in retinal vascular permeability [4, 7]. Therefore, 
reducing intraocular concentrations of IL-6 and VEGF is 
needed for reduction of macular edema associated with 
BRVO. Intravitreal steroids are extremely effective in 
neutralizing inflammatory cytokines including IL-1, IL-6, 
ICAM-1 and MCP [7, 10]. 
Previous studies have demonstrated that intravitreal 
bevacizumab compared to intravitreal triamcinolone 
acetonide resulted in a similar reduction in macular 
edema and improvement in visual acuity in BRVO-
associated macular edema [11-13]. One study reported 
that intravitreal injection of triamcinolone, bevacizumab, 
or a combination of bevacizumab and triamcinolone 
acetonide yielded similar therapeutic effects on macular 
edema at 1 month, but with intravitreal bevacizumab 
yielding better results in visual acuity at 6 months [14]. 
Other studies have reported that combined treatment 
with intravitreal bevacizumab and triamcinolone 
acetonide offered no vision advantage compared to 
intravitreal bevacizumab alone after 6 months [15]. We 
believe that concurrent administration of intravitreal 
triamcinolone acetonide and bevacizumab neutralized 
VEGF as well as all inflammatory cytokines, and promoted 
complete resolution of macular edema with subsequent 
vision improvement in our patient.  
Although it was a case report, our results suggest that dual 
medication use including intravitreal injection of 
bevacizumab and triamcinolone acetonide is an 
encouraging and effective strategy in the treatment of 
BRVO-associated CME. Many studies reported traditional 
macular grid laser and anti-VEGF agents alone with 
variable outcomes; however, we provided a successful 
alternate treatment option for patients with BRVO-
associated CME refractory to conventional interventions, 
which is the major strength of our study. Further 
randomized controlled clinical studies are necessary to 
determine the impact of this treatment strategy in the 
management of BRVO-associated CME. Overall, a 
balanced approach will incorporate early intervention to 
yield better visual and anatomic outcomes, particularly in 
eyes with fovea-involving macular edema. 
CONCLUSION 
In summary, simultaneous administration of intravitreal 
anti-VEGF therapy and triamcinolone acetonide resulted 
in a complete resolution of BRVO-associated recalcitrant 
macular edema, which was unresponsive to traditional 
treatment. This combined approach yielded a promising 
response and superior visual outcome in our patient. 
While a final consensus has not yet been reached 
regarding the optimal treatment algorithm for BRVO-
associated CME resistant to established treatment 
patterns, medical decision should be tailored individually. 
Coupling intravitreal anti-VEGF therapy with 
triamcinolone acetonide has a promising role in the 
management of CME associated with BRVO. 
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